CAJ | 학술논문

目的观察新辅助化疗对晚期卵巢癌的临床意义.方法78例晚期卵巢癌患者随机分为新辅助化疗组(A 组38例)及先期手术组(B 组40例),新辅助化疗组采用 TP 方案(紫杉醇联合顺铂)化疗2~3周期后予肿瘤细胞减灭术,术后继续该方案化疗4~6周期;先期手术组施行肿瘤细胞减灭术后使用同一方案化疗6~8周期,评价新辅助化疗的临床疗效.结果新辅助化疗2~3周期后有效率71.05%,无患者出现疾病进展.手术基本切净率81.58%,与先期手术组比较有统计学差异(P <0.01);缩短了手术时间,减少了术中出血量,术后并发症减少(P <0.01);中位生存期33.6个月,1年生存率79.8%(30/38),3年生存率36.8%(14/38),均明显优于先期手术组(P <0.05).结论 TP 方案新辅助化疗2~3周期能降低晚期卵巢癌的分期,提高手术切净率,改善患者预后,可在临床推广使用.
목적관찰신보조화료대만기란소암적림상의의.방법78례만기란소암환자수궤분위신보조화료조(A 조38례)급선기수술조(B 조40례),신보조화료조채용 TP 방안(자삼순연합순박)화료2~3주기후여종류세포감멸술,술후계속해방안화료4~6주기;선기수술조시행종류세포감멸술후사용동일방안화료6~8주기,평개신보조화료적림상료효.결과신보조화료2~3주기후유효솔71.05%,무환자출현질병진전.수술기본절정솔81.58%,여선기수술조비교유통계학차이(P <0.01);축단료수술시간,감소료술중출혈량,술후병발증감소(P <0.01);중위생존기33.6개월,1년생존솔79.8%(30/38),3년생존솔36.8%(14/38),균명현우우선기수술조(P <0.05).결론 TP 방안신보조화료2~3주기능강저만기란소암적분기,제고수술절정솔,개선환자예후,가재림상추엄사용.
Objective To observe the clinical significance of neoadjuvant chemotherapy for advanced ovarian cancer. Method 78 patients with advanced ovarian cancer, divided into the neoadjuvant chemotherapy group(group A 38cases)and the advanced operation group(group B40 cases).The neoadjuvant chemotherapy group was given a TP scheme(paclitaxel in conjunction with cisplatin),with 1to 3 cycles of chemotherapy,and then received cytoreductive surgery,post-op this group continued this program of chemotherapy for 4~6 cycles; the advanced operation group only used the same program of chemotherapy for 6~8 cycles after receiving cytoreductive surgery, in order to evaluate the clinical curative effect of neoadjuvant chemotherapy. Results The efficiency rate of neoadjuvant chemotherapy after 2 to 3 cycles was 71.05%,no patients experienced any disease progression. The initial incision length of the operation(for Group A)is reduced by 81.58%,compared to the advanced operation group(P<0.01),this is statistically significant. Neoadjuvant chemotherapy shortened the surgery time,decreased blood loss volume,and has fewer postoperative complications(P<0.01);the median survival rate is 33.6 months, 1-year survival rate is 79.8% (30/38 patients), a 3-year survival rate 36.8%(14/38 patients), this is significantly better than the advanced operation group(P<0.05)Conclusion TP scheme neoadjuvant chemotherapy for 2~3 cycles can reduce advanced ovarian cancer’s staging, enhance the operation precision rate,improve the prognosis for patients, can be used in the clinical practice